Cohort1: dose level 1
|
Administration route |
intraarticular injection |
Dosage |
1.2E12 vg/ CMC joint, 1.2E12 vg/ MCP joint, 0.6E12 vg/ PIP joint or 0.3E12 vg/ DIP joint single intra-articular injection |
Age |
Adult, Older_Adult |
Adverse reactions |
No serious clinical adverse events |
References |
PMID:
34626797
|
|
Cohort2: dose level 2
|
Administration route |
intraarticular injection |
Dosage |
1.2E12 vg/ CMC joint, 1.2E13 vg/ MCP joint, 0.6E13 vg/ PIP joint or 0.3E13 vg/ DIP joint single intra-articular injection |
Age |
Adult, Older_Adult |
Adverse reactions |
No serious clinical adverse events |
References |
PMID:
34626797
|
|
Cohort3: dose level 3
|
Administration route |
intraarticular injection |
Dosage |
1.2E12 vg/ CMC joint, 1.2E13 vg/ MCP joint, 0.6E13 vg/ PIP joint or 0.3E13 vg/ DIP joint or maximum Tolerated Dose (MTD) single intra-articular injection |
Age |
Adult, Older_Adult |
Adverse reactions |
No serious clinical adverse events |
References |
PMID:
34626797
|
|